论文部分内容阅读
目的观察进展期胃癌患者应用奥沙利铂联合替吉奥(SOX方案)治疗的临床疗效及不良反应。方法选择青岛市中心医院2010年1月至2014年2月收治的进展期胃癌78例,随机分为观察组和对照组各39例。观察组采用SOX方案化疗,对照组采用FOLFOX4方案(奥沙利铂联合氟尿嘧啶和亚叶酸钙)化疗,两个周期后评价两组患者的临床疗效和不良反应。结果观察组有效率为56.41%,疾病控制率为76.92%,对照组有效率为56.41%,疾病控制率为74.36%,2组比较差异无统计学意义(P>0.05);观察组白细胞下降及恶心呕吐发生率明显低于对照组,差异有统计学意义(P<0.05)。其余不良反应,如红细胞下降、血小板下降、腹泻、外周神经症状、手足综合征、肝功能异常等相似,差异无统计学意义(P>0.05)。结论奥沙利铂联合替吉奥治疗进展期胃癌临床疗效好,不良反应较轻,患者耐受性较好,有利于提高患者化疗的依从性,能更好地配合治疗。
Objective To observe the clinical efficacy and side effects of oxaliplatin combined with tirofiban (SOX regimen) in patients with advanced gastric cancer. Methods 78 cases of advanced gastric cancer admitted to Qingdao Central Hospital from January 2010 to February 2014 were randomly divided into observation group (39 cases) and control group (39 cases). The observation group was treated with SOX regimen, the control group was treated with FOLFOX4 regimen (oxaliplatin combined with fluorouracil and leucovorin), and the clinical efficacy and adverse reactions were evaluated after two cycles. Results The effective rate of observation group was 56.41%, disease control rate was 76.92%, control group was 56.41%, disease control rate was 74.36%, there was no significant difference between the two groups (P> 0.05) The incidence of nausea and vomiting was significantly lower than that of the control group, the difference was statistically significant (P <0.05). The remaining adverse reactions, such as decreased red blood cells, thrombocytopenia, diarrhea, peripheral neurological symptoms, hand-foot syndrome, liver dysfunction and other similar, the difference was not statistically significant (P> 0.05). Conclusion The combination of oxaliplatin and tioguanide in the treatment of advanced gastric cancer has good curative effect, less adverse reactions and better tolerability. It is helpful to improve the compliance of patients with chemotherapy and better cooperate with the treatment.